Actuate Therapeutics has gained OMPD from the EMA for elraglusib aimed at treating pancreatic ductal adenocarcinoma (PDAC).
GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.
Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback